Phenotype of Human CD45+ Cells in the Bone Marrow of Mice Injected With Unsorted Cord Blood
| Treatment (no. of mice) . | Proportion of CD45+ Human Cells (range) . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lymphocytes . | Myelocytes . | CD19 . | CD20 . | IgM . | CD33 . | CD13 . | CD14 . | CD15 . | CD34 . | |
| NoGF | 60 | 9 | 77 | 47 | 8 | 15 | 12 | 6 | 6 | 10 |
| (23) | (35-84) | (2-18) | (48-96) | (30-68) | (5 mice, pooled) | (5 mice, pooled) | (5 mice, pooled) | (1-12) | (1-14) | (2-21) |
| SCF/GM-CSF/IL-3 | 34 | 32 | 53 | 37 | 13 | 33 | 27 | 16 | 14 | 15 |
| (5) | (7-81) | (9-48) | (43-74) | (26-51) | (8-19) | (8-44) | (8-39) | (0.2-24) | (4-20) | (2-21) |
| IL-7 | 55 | 12 | 73 | 50 | — | — | — | 6 | — | 7 |
| (10) | (38-68) | (5-25) | (62-89) | (26-68) | (3-10) | (3-16) | ||||
| FL | 36 | 34 | 47 | 29 | 4 | 48 | 37 | 14 | 17 | 8 |
| (8) | (20-50) | (15-45) | (28-71) | (18-53) | (2-25) | (5-13) | ||||
| FL/IL-7 | 14 | 44 | 28 | 21 | — | — | — | 29 | — | 12 |
| (8) | (3-29) | (36-60) | (5-44) | (4-31) | (18-36) | (6-16) | ||||
| FL/SCF/IL-7 | 16 | 36 | 23 | — | — | — | — | 12 | 10 | 8 |
| (4) | (6-25) | (14-49) | (18-28) | (14-17) | (9-15) | (5-12) | ||||
| Treatment (no. of mice) . | Proportion of CD45+ Human Cells (range) . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lymphocytes . | Myelocytes . | CD19 . | CD20 . | IgM . | CD33 . | CD13 . | CD14 . | CD15 . | CD34 . | |
| NoGF | 60 | 9 | 77 | 47 | 8 | 15 | 12 | 6 | 6 | 10 |
| (23) | (35-84) | (2-18) | (48-96) | (30-68) | (5 mice, pooled) | (5 mice, pooled) | (5 mice, pooled) | (1-12) | (1-14) | (2-21) |
| SCF/GM-CSF/IL-3 | 34 | 32 | 53 | 37 | 13 | 33 | 27 | 16 | 14 | 15 |
| (5) | (7-81) | (9-48) | (43-74) | (26-51) | (8-19) | (8-44) | (8-39) | (0.2-24) | (4-20) | (2-21) |
| IL-7 | 55 | 12 | 73 | 50 | — | — | — | 6 | — | 7 |
| (10) | (38-68) | (5-25) | (62-89) | (26-68) | (3-10) | (3-16) | ||||
| FL | 36 | 34 | 47 | 29 | 4 | 48 | 37 | 14 | 17 | 8 |
| (8) | (20-50) | (15-45) | (28-71) | (18-53) | (2-25) | (5-13) | ||||
| FL/IL-7 | 14 | 44 | 28 | 21 | — | — | — | 29 | — | 12 |
| (8) | (3-29) | (36-60) | (5-44) | (4-31) | (18-36) | (6-16) | ||||
| FL/SCF/IL-7 | 16 | 36 | 23 | — | — | — | — | 12 | 10 | 8 |
| (4) | (6-25) | (14-49) | (18-28) | (14-17) | (9-15) | (5-12) | ||||
The proportion of CD45+ human cells coexpressing the indicated cell-surface phenotype is given as the average (and range) from the indicated number of mice. The lymphocyte and myelocyte percentages were calculated as described in Fig 3.